Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313382671> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W4313382671 endingPage "70.4" @default.
- W4313382671 startingPage "70.4" @default.
- W4313382671 abstract "Abstract Prostate cancer is the most common type of cancer in men. Immunotherapies such as Sipuleucel-T have shown that stimulating the immune system to target the prostate is a viable therapeutic option. Inovio is a clinical-stage biotechnology company that uses DNA vaccines as a novel immunotherapy strategy. An advantage to plasmid DNA vaccine therapy is the ability to encode adjuvants within the vaccine in order to increase immunogenicity and efficacy. We conducted an adjuvant screen in BALB/c mice with 25 candidate plasmid encoded genetic adjuvants in combination with the prostate cancer specific tumor-associated antigen STEAP1. Antigen-specific T cell responses were measured by IFNg ELISpot. The screen revealed that the addition of a plasmid encoding dendritic cell (DC)-activating Fms-like tyrosine kinase 3 ligand (Flt3L) fused to an Fc domain, significantly increased antigen-specific T cells (p<0.001, 2.8 fold). Mice treated with Flt3L-Fc had an enhanced immune response to STEAP1 vaccination as early as 7 days post dose 1 (p<0.01, 2.4 fold), which developed into an enhanced memory response measured 12 weeks later (p<0.001, 8.5 fold). Flow cytometry showed that Flt3L-Fc increased DC populations at the site of injection and at the draining lymph node 8 days following the initial vaccination. DCs are considered the most potent antigen-presenting cells in the immune system and DCs at the tumor site have been shown to be critical for T cell immunity. Our data shows that enhancing DC populations and function through the use of a genetic adjuvant can enhance the immunogenicity of a DNA cancer vaccine. Future studies will assess the efficacy of Flt3L-Fc in combination with STEAP1 in a mouse tumor model." @default.
- W4313382671 created "2023-01-06" @default.
- W4313382671 creator A5016263949 @default.
- W4313382671 creator A5027807999 @default.
- W4313382671 creator A5060854291 @default.
- W4313382671 creator A5069226900 @default.
- W4313382671 creator A5080495677 @default.
- W4313382671 date "2019-05-01" @default.
- W4313382671 modified "2023-09-26" @default.
- W4313382671 title "Adjuvant screen identifies DC modifying growth factor Flt3 ligand as candidate for prostate cancer DNA vaccine" @default.
- W4313382671 doi "https://doi.org/10.4049/jimmunol.202.supp.70.4" @default.
- W4313382671 hasPublicationYear "2019" @default.
- W4313382671 type Work @default.
- W4313382671 citedByCount "0" @default.
- W4313382671 crossrefType "journal-article" @default.
- W4313382671 hasAuthorship W4313382671A5016263949 @default.
- W4313382671 hasAuthorship W4313382671A5027807999 @default.
- W4313382671 hasAuthorship W4313382671A5060854291 @default.
- W4313382671 hasAuthorship W4313382671A5069226900 @default.
- W4313382671 hasAuthorship W4313382671A5080495677 @default.
- W4313382671 hasConcept C121608353 @default.
- W4313382671 hasConcept C126322002 @default.
- W4313382671 hasConcept C147483822 @default.
- W4313382671 hasConcept C167508917 @default.
- W4313382671 hasConcept C203014093 @default.
- W4313382671 hasConcept C22070199 @default.
- W4313382671 hasConcept C2776090121 @default.
- W4313382671 hasConcept C2777701055 @default.
- W4313382671 hasConcept C2777863537 @default.
- W4313382671 hasConcept C2778378633 @default.
- W4313382671 hasConcept C2779053233 @default.
- W4313382671 hasConcept C2780192828 @default.
- W4313382671 hasConcept C2780801004 @default.
- W4313382671 hasConcept C2780868878 @default.
- W4313382671 hasConcept C502942594 @default.
- W4313382671 hasConcept C71924100 @default.
- W4313382671 hasConcept C86803240 @default.
- W4313382671 hasConcept C8891405 @default.
- W4313382671 hasConceptScore W4313382671C121608353 @default.
- W4313382671 hasConceptScore W4313382671C126322002 @default.
- W4313382671 hasConceptScore W4313382671C147483822 @default.
- W4313382671 hasConceptScore W4313382671C167508917 @default.
- W4313382671 hasConceptScore W4313382671C203014093 @default.
- W4313382671 hasConceptScore W4313382671C22070199 @default.
- W4313382671 hasConceptScore W4313382671C2776090121 @default.
- W4313382671 hasConceptScore W4313382671C2777701055 @default.
- W4313382671 hasConceptScore W4313382671C2777863537 @default.
- W4313382671 hasConceptScore W4313382671C2778378633 @default.
- W4313382671 hasConceptScore W4313382671C2779053233 @default.
- W4313382671 hasConceptScore W4313382671C2780192828 @default.
- W4313382671 hasConceptScore W4313382671C2780801004 @default.
- W4313382671 hasConceptScore W4313382671C2780868878 @default.
- W4313382671 hasConceptScore W4313382671C502942594 @default.
- W4313382671 hasConceptScore W4313382671C71924100 @default.
- W4313382671 hasConceptScore W4313382671C86803240 @default.
- W4313382671 hasConceptScore W4313382671C8891405 @default.
- W4313382671 hasIssue "1_Supplement" @default.
- W4313382671 hasLocation W43133826711 @default.
- W4313382671 hasOpenAccess W4313382671 @default.
- W4313382671 hasPrimaryLocation W43133826711 @default.
- W4313382671 hasRelatedWork W1481917790 @default.
- W4313382671 hasRelatedWork W2009090497 @default.
- W4313382671 hasRelatedWork W2043775195 @default.
- W4313382671 hasRelatedWork W2090698640 @default.
- W4313382671 hasRelatedWork W2095304551 @default.
- W4313382671 hasRelatedWork W2357951527 @default.
- W4313382671 hasRelatedWork W2411712784 @default.
- W4313382671 hasRelatedWork W2594077466 @default.
- W4313382671 hasRelatedWork W2982698179 @default.
- W4313382671 hasRelatedWork W3109192410 @default.
- W4313382671 hasVolume "202" @default.
- W4313382671 isParatext "false" @default.
- W4313382671 isRetracted "false" @default.
- W4313382671 workType "article" @default.